Targeting HER2 heterogeneity in breast and gastrointestinal cancers

Area of Science:

• Oncology
• Molecular Biology
• Cancer Biomarkers

Background:

• Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% of breast and gastric cancers and 3% of colorectal carcinomas.
• HER2-targeted therapies are effective for patients with HER2-overexpressing tumors.
• HER2 expression can vary within a tumor (intralesional heterogeneity), between different tumor sites (interlesional heterogeneity), and over time during treatment (temporal heterogeneity).

Purpose of the Study:

• To highlight the challenges in defining and characterizing HER2 heterogeneity in solid tumors.
• To emphasize the impact of spatial and temporal HER2 heterogeneity on treatment response and resistance.
• To underscore the need for HER2 heterogeneity characterization as a predictive biomarker for guiding treatment modulation.

Main Methods:

• Review of existing literature on HER2 expression heterogeneity in solid tumors.
• Analysis of the prevalence and predictive role of HER2 heterogeneity across different cancer types.
• Discussion of the challenges in implementing HER2 heterogeneity as a reproducible biomarker.

Main Results:

• HER2 heterogeneity is a common phenomenon across HER2-overexpressing solid tumors.
• Spatial and temporal variations in HER2 expression can influence the efficacy of HER2-directed agents.
• The predictive value of HER2 heterogeneity varies among different tumor types.

Conclusions:

• HER2 heterogeneity presents significant challenges for accurate diagnosis and treatment planning.
• Characterizing HER2 heterogeneity is essential for optimizing therapeutic strategies.
• Implementing reproducible methods for assessing HER2 heterogeneity could improve patient outcomes by guiding treatment decisions.